Aztreonam and avibactam
Kathryn Dzintars, Pharm.D., BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Emblaveo (Aztreonam/Avibactam) is indicated in patients 18 years of age and older who have limited to no alternative treatment options for the treatment of complicated intra-abdominal infections (cIAI)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Resistant Gram-negative infections caused by metallo-β-lactamase producing organisms (e.g., NDM)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.